Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

• Published in: Emerging microbes & infections Vol. 9; no. 1; pp. 382 - 385
• Main Authors: Tian, Xiaolong, Li, Cheng, Huang, Ailing, Xia, Shuai, Lu, Sicong, Shi, Zhengli, Lu, Lu, Jiang, Shibo, Yang, Zhenlin, Wu, Yanling, Ying, Tianlei
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2020; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: 2019-nCoV; ACE2; Amino Acid Sequence; Antibodies, Monoclonal - immunology; Antibodies, Viral - immunology; Betacoronavirus - immunology; Binding sites; Coronavirus Infections; Coronaviruses; COVID-19; Cross Reactions; Humans; Letter; Monoclonal antibodies; monoclonal antibody; Pneumonia, Viral; Protein Structure, Tertiary; Proteins; RBD; SARS Virus - immunology; SARS-CoV; SARS-CoV-2; Spike Glycoprotein, Coronavirus - immunology; ACE2; 2019-nCoV; monoclonal antibody; RBD; SARS-CoV

The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity...